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RECENT experimental investigations of plasma cell myeloma have been directed
mainly towards the elucidation of problems of protein synthesis in the myeloma
cell (Nathan, Fahey and Potter, 1958; Vasquez, 1958; Truax, Bray and Perry
1961), and the effects of chemotherapy on tumour progression in vivo (Kay,
Ledlie and Sbresni, 1959; Denman and Ward, 1960; Benefiel, Helsper and Sharp,
1960; Hayes, Spurr and Hines, 1961). Morphological studies have been
concerned with details of ultrastructure as revealed by the electron microscope
(Braunsteiner, Fellinger and Pakesch, 1957; Dalton, Potter and Merwin, 1961).
In our present work we have investigated the dynamic morphology of myeloma
tells, using phase contrast optics and time-lapse cinematography. We have been
able to correlate these findings with similar work on the rat plasma cell carried
out by Thiery (1960) and personal observations on normal rat plasma cells.
The myeloma cells have been exposed in vitro to a recently developed chemo-
therapeutic compound, 1-aminocyclopentanecarboxylic acid (NSC-1026), which
has proved useful in the treatment of multiple myelomatosis (Benefiel et al., 1960)
at a total dose level of 400-800 mg./kg. body weight. At the same time, pre-
liminary work has been carried out on the chromosomal pattern of growing
peripheral blood cells of myeloma patients. While no " marker " chromosomes
weredetected in our material, itis interesting tonote that chromosomal aberrations
have recently been established in sternal marrow preparations from a related
disease, Waldenstrom's macroglobulinaemia (Bottura, Ferrari and Veiga, 1961).
Samples of growing peripheral blood cells were also investigated before and after
a course of NSC-1026.
MATERIALS AND TECHNIQUIES
Material for examination was obtained from three cases of multiple myeloma.
Case 1.-M.L. Female, 55 years. She complained of a lump (5 x 3 X 3
cm.) on the right side of the head. The tumour had been growing over a period
of five months. X-rav demonstrated a destructive process in the underlying
bone and histological examination of a biopsy showed the typical appearance of
myeloma. Specimens of the tumour, bone marrow and peripheral blood were
-taken for study in vitro. The next day, the patient received the first of 10 daily
intravenous injections of NSC-1026. Two days after the last injection repeat
samples of blood, bone marrow and tumour were obtained.
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('ase 2.-W.M. Male, 70 years. There was a 14 month history of bone
pain diagnosed elsewhere as due to multiple myeloma on the basis ofX-ray findings
and marrow biopsy. Eight months ago he received 17 X-ray treatments to the
thoracic spine and later was started on a course of urethane which had to be dis-
continued after a month on account of nausea. On examination he was an
emaciated, ill subject. Samples ofblood and bone marrow were taken for culture
(bone marrow smears confirmed the diagnosis). Similar material was obtained
five days after completing a course ofNSC-1026 therapy.
Case 3.-N.R. Female, 63 years. Four years ago a complaint of aching
bones led to bone marrow biopsy which established the diagnosis of multiple
myeloma. A trial of urethane at this time was discontinued on account of
leucopenia. She has remained remarkably well since then, although X-rays show
extensive osteolytic lesions in the skeleton. Recent exacerbation of bone pain
led to a trial of NSC-1026 therapy. Specimens of blood and bone marrow were
obtained before commencing therapy.
Culture techniques
Explants of tumour, derived from Case 1, were grown (a) under narrow cello-
phane strips in modified Rose chambers (Rose et al., 1958) using Eagle's medium
enriched by 10 per cent human serum, (b) on plasma clot in T30 flasks, using
10 per cent horse serum in Eagle's medium. Subculture was carried out by
trypsinization (0-2 per cent trypsin (Nutritional Biochemicals Corporation) for
10 minutes) and transfer to fresh plasma clot.
Twenty-five to 40 ml. samples of venous blood were collected in tubes, and
cultures of the buffy coat were prepared, using bactophytohemagglutinin (Difco)
according to techniques already established (Hungerford et al., 1959; Nowell,
1960; Ohnuki, Awa and Pomerat, 1962). Material from all three patients was
was available for study but owing to a temporary change in the character of
bactophytohemagglutinin, comparable samples of blood before and after NSC-
1026 therapy were successfully grown only in Case 1.
Explants of bone marrow were grown variously; (a) in Rose chambers under
cellophane; (b) on plasma clot in T30 flasks-both as described for tumor ex-
plants; (c) on glass, in T30 flasks, using Eagle's medium, with 10 per cent horse
serum, for chromosome studies: after 18 hours culture the cells were exposed to
colchicine (0 05 ml. of 1/10,000 dilution to 5 ml. of medium) for three hours before
squashing and microscopic examination; (d) heparinized samples were grown
according to the buffv coat technique for peripheral blood.
RESULTS
Behaviour of myeloma cells in tissue culture
The outgrowth from bone marrow and tumour explants always contained
an admixture of other blood elements and fibroblasts, in addition to the myeloma,
cells. The myeloma cells were identified using phase contrast optics, by their
typical morphology and cytoplasmic movements, correlated with experience
gained in examination before and after fixation and staining.
Cinematographic recordings were made of myeloma cells and their dynamic
behaviour was subsequently analvsed, making particular use of the Vanguard
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analyser which allows viewing of enlarged pictures of individual film frames at
any desired speed. Four different types of cell movement were observed. (1)
A lesser or greater part ofthe cell mernbrane may show a fine undulating activity.
Some cells have shown a unusually marked membrane undulation (Fig. 1) but in
general this cell movement is only noticeable when the process is speeded up by
time-lapse cinematography. Thiery (1960), working on rat plasma cells has stres-
sed that it is the plasmablast which is characterized by undulation of the cell
membrane, which was not observed by him in the mature plasma cell. Almost
all myeloma cells, in our studies, have shown this type of activity. (2) At one
or more sites on the cell membrane, a thick pulsating extension of cytoplasm may
be formed (Fig. 7, 8, 9). These pseudopodia extend and retract rapidly, taking
about 30 seconds to complete the cycle, and showing a period ofrest (usually about
30 seconds) between successive pulsations at the same site on the cell membrane.
At the tip of the pseudopodium, there is an active undulation of the membrane
and secondary protrusions of fine processes may also be seen in this area (Fig. 2).
EXPLANATION OF PLATES
All the phase contrast microphotographs were taken on living cells, except Fig. 23-26 inclusive.
FIGT. 1. Myeloma cell showing remarkable undulation of the cell membrane. Phase Contrast.
x 2000.
FIG. 2.- Myeloma cell exhibiting two short pseudopodal extensions of the cytoplasm; fine
cytoplasmic processes are seen at the tips of the pseudopods and elsewhere on the cell
mnargin. P.C. x 2600.
FIG. 3. Myeloma cell showing grossly eccentric position of the nucleus. P.C. x 2600.
Fi(e. 4. Myeloma cell which showed fine undulating activity of the margin at the left lower
pole. P.C. x 2600.
Fic.. 5. Same cell as Fig. 4, showing broad pseudopodal extension of the cytoplasm at the
site of undulation. P.C. x2600.
FIG. 6. The fine network seen in the cytoplasm of this degenerating myeloma cell is due
to vacuolisation of the endoplasmic reticultum. (The large white area to the left of the
nucleus is an artefact.) P.C. x 2600.
FIG. 7, 8, 9. Rapid cytoplasmic pulsation in myeloma cells. Same field photographed at
0, 14, 35 seconds. P.C. x 900 approximately.
FIG. 10, 11, 12. Division of myeloma cell showing metaphase, anaphase and telophase
respectively. P.C. x 1000 approximately.
FIG. 13. Untreated explant of myelomatous tumour (left half of field) with healthy out-
growth of myeloma cells and fibroblasts. May-Grunwald-Giesma. x 310.
FIG. 14.-Myeloma explant treated for 30 hours with 1 per cent NSC-1026. Comparable field
to that in Fig. 13. Degenerative changes are seen in the cells of the outgrowth and in the
original explant. M.G.G. x 310.
FIG. 15.-Myeloma cells after 15 days in vitro. Prominent Golgi areas are seen, there is
considerable variation in cell shape, and nuclei are often grossly eccentric. Binucleate
and multinucleate forms are present. M.G.G. x 785.
FIG. 16. Two spindle-shaped myeloma cells are seen in the upper part of the photograplh.
These may be compared with two lighter-stained fibroblasts, in the middle and left lower
parts of the field. Fifteen davs in vitro. M.G.G. x 785.
FIG. 17-22.-Sanme field photographed over a period of 5 hours. One myeloma cell (arrowed)
shows irregular elongatioil and contraction, leading finally to cell death (Fig. 22). Other cells
in the field show similar spasmodic elongation and contraction, in lesser degree. Treated
with 0 5 per cent NSC-1026. P.C. x 750 approximately.
FicG. 23-26. Squash preparations of metaphase plates in buffy coat cultures from Case 1
after treatment with NSC-1026. All stained by acetic-orcein and photographed with
phase-contrast optics.
FIG. 23. Normal metaphase.
FIG. 24. One exainple of abnorimial chromosome morphology. The idiograni of this
cell is seen in Fig. 28.
FIG. 25. Translocation of chromosomes.
FIG. 26.- Chromosomne showing breakage.BRITISH JOIURNAL OF CANCER
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Cell movement can be attributed to this active pulsatile movement of cytoplasm,
since elements showing this activity are seen to move around the field. Pro-
gression appears to be haphazard, the myeloma cell showing slight darting move-
ments in all directions, leading to final displacement from the original site. From
Thiery's description (1960) the rat plasma cell movement is a slower smoother
process, characterized by cytoplasmic extension in one direction after which the
rest of the cell becomes displaced along the same axis. Our own observations
on the rat plasma cell confirm this impression. (3) Occasionally, myeloma cells
show a single extended protrusion of cytoplasm, which develops from anl area
of rapid membrane undulation (Fig. 4, 5). This process remains stable for long
periods, up to 15 minutes. At the tip of the process, however, there is very
active undulation of the cell membrane. (4) Fine membranous extensions of
cytoplasm may be seen on the periphery ofthe myeloma cell (Fig. 2). These thin
protrusions extend and retract fairly rapidly, lasting about 20 seconds from start
to finish, and appearing at many points on the circumference of the cell. This
activity was seen by Thiery in rat plasmablasts, and he has shown by electron
microscopy that small droplets of fluid are imprisioned by these thin pseudopodia
of cell membrane, constituting a micropinocytic process. Vacuoles have not
been observed by phase contrast examination of myeloma cells but no doubt the
vacuoles are too small to be observed by this technique.
Morphology of myeloma cells in tissue culture
Myeloma cells generally retained their characteristic morphology for as long as
6 weeks in vitro, which was the limit of the experiments. Puring the first three
weeks, their numbers tended to be static and only an occasional mitotic figure
was identified as certainly occurring in a plasma cell. In 1500 feet of cinemato-
graphic film, a single mitosis was seen in a typical myeloma cell (Fig. 10, 11, 12).
Despite this, examination of cultures fixed and stained at intervals during the
first two weeks showed an increase in the number of binucleate and multinucleate
myeloma cells (Fig. 15), suggesting that growth, rather than maintenance, was
being achieved in the culture chambers. In later weeks, however, the myeloma
cells became less numerous, in contrast to an overwhelming fibroblastic outgrowth.
This decrease in myeloma cells was probably due, in large part, to death of the
cells but in part it was the result of transformation of occasional myeloma cells
into a fibroblast-like element. Elongation of plasma cells to a spindle-shaped
form was seen in many ofthe cultures, and photographic records were made using
phase contrast microscopy. Examination of these small spindle cells in fixed
and stained preparations (May-Gruinwald-Giemsa) showed that the nucleus
retained the characteristic chromatin network of the myeloma cell while the
cytoplasm exhibited the typical pale juxta-nuclear zone and deep blue coloration
elsewhere due to its high content of ribonucleic acid. At this stage it was simple
to differentiate from the larger, pale fibroblast with its vesicular nucleus (Fig. 16).
Stained preparations ofmyeloma cells growing in culture often show a peculiar
exaggeration of the normally eccentric position of the cell nucleus, so that the
nucleus appears to lie partly outside the cytoplasm (Fig. 15). While this might
have been considered a staining or fixation artefact, phase contrast photographs
ofliving cells show an identical morphology (Fig. 3). We do not suggest that the
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plasma membrane is not intact, but merely wish to draw attention to this charac-
teristic appearance of the myeloma cell in culture.
Unlike epithelial and fibroblastic cells, myeloma cells do not flatten out well
on the glass surface of the culture chamber. This propensity militated against
good high-power observation and photography by phase-contrast optics. For
instance, the endoplasmic reticulum was very difficult to demonstrate. Thiery
has obtained good phase-contrast photographs of the endoplasmic reticulum in
the rat plasma cell, by examination in a thin preparation, and we have confirmed
his results in similar preparations of rat plasma cells. In the case of human
myeloma cells, we have dismantled Rose chamber cultures and placed the chamber
coverslip on a glass slide with a little fluid between the two surfaces. Under these
conditions, the myelonia cells remain active for 15 to 30 minutes, and oil-immersion
photography of more flattened cells is rendered possible. The endoplasmic
reticulum has been identified and recorded (Fig. 6) in the living myeloma cell.
although only in cells which were degenerating and about to die.
Effect of treatment with NSC-1026 in vitro
Cultures ofmyeloma tumour and bone-miarrow tissue were exposed to standard
medium containing 0-2, 0-5, 0 75 and 1 per cent NSC-1026. Since these are
relatively high concentrations, it should be stressed that the effective dosage of a
drug in vitro may not run pari passu with the dosage in man (Painter, Pomerat
and Ezell, 1949). Cinematographic records of cell activity were made on some
of the preparations while others were treated for 1 to 3 days followed by fixation
and staining. With 0-2 per cent NSC-1026, no visible change was detected in
living or fixed material. Cultures exposed to 1-0 per cent NSC-1026 showed
evidence of cell damage and death within one hour; most cells were killed by 12
hours treatment and all cells were dead at 30 hours. Continuous treatment with
0 5 and 0 75 per cent NSC-1026 over a period of 3 days led to death of about half
the cells in the culture.
Using time-lapse cinematography, we were able to analyse the dynamic
changes associated with toxicity at dose levels of 0-5 and 0 75 per cent. The most
common change which indicated severe cell damage and early death was the
cessation of membrane undulation. Degeneration and rounding up of the cell
body occurred a few minutes after the cell membrane movement stopped. One
peculiar feature, not necessarily presaging death, was a vigorous rocking movement
in the myeloma nucleus. The nucleus would rock back and forth through an
angle of 160-1800, taking an average of 16 minutes to complete each cycle. A
small percentage of myeloma cells responded in a different and unusual manner:
these cells became elongated, showing spasmodic contractions and elongations
over a period of 4 to 10 hours (Fig. 17-22), associated with rapid intracellular
movements of the nucleus along the long axis of the elongated cell. Eventually
the cell would degenerate and become rounded up and granular in appearance.
We had no way of ascertaining, from the cine records, whether any particular
maturation stage of the myeloma cell was responsible for the activity described.
Examination of stained preparations showed that the cells in the original
explant, as well as in the outgrowth, were killed and subsequently lysed, following
exposure to 1 per cent NSC-1026 (Fig. 13, 14). At lower levels of dosage we
could not detect any specific action of NSC-1026--adventitial cells and myeloma
cells appeared to be affected equally.MULTIPLE MYELOMA
Chromosomal investigation
On examination of the buffy coat culture of Case 1 before treatment, 50 well-
spread metaphase plates were available for study. Each of these cells had the
diploid complement of 46 chromosomes which were of normal morphology. In
preparations obtained after treatment of the patient with NSC-1026, a total of
221 well-spread metaphase plates were examined. The results are shown in
Table I.
TABLE I.-Analysis ofMetaphase Plates in Buffy Coat Culture Following Treatment
with NSC-1026
Chromosome morphology Number of cells
Normal . . 215*
Abnormal karyotype 2
Chromosome breakage 4t
* Four showed variation in chromosome number 47(2), 48(1), 50(1).
t Estimated chromosome number, 46. Two cells showed typical translocation.
Some variation in the chromosome number, similar to that detailed in the
table, has been reported by other workers (Nowell and Hungerford 1960) in
tissues grown in vitro and has been the common experience in our own
laboratories (Ohnuki et al., 1962). Similarly, we have observed chromatid
breakage in control cultures of normal adult humans. Quite unusual, however,
in our hands is the finding of 2 cells with abnormal karyotype (Fig. 23, 24, 27, 28)
and 4 cells showing chromosome breakage and translocation (Fig. 25, 26). There
can be little doubt that these changes represent an effect of in vivo treatment
with NSC-1026. Indeed, chromosome breakage and translocation is a common
event following treatment of growing cells with X-rays or radiomimetic drugs
(Kaufmann, 1954; Lea, 1955; Biesele, 1958). It must be stressed that there is
no way of knowing which circulating blood cells have undergone mitosis in buffy
coat cultures ofour patient. Monocytes and possibly lumphocytes are thought to
be responsible for the usual growth in this type of culture. Smear examination
of the blood in our patient showed the presence of occasional plasmablasts and
more mature plasma cells, and therefore some presumably malignant cells may
have contributed to the mitoses observed, in the samples taken before and after
treatment. While this uncertainty remains, it is clear that buffy coat culture
can help with the estimation of the efficacy of anti-tumour chemotherapy. We
can judge whether the dose-level is sufficient to cause toxic changes in the patient's
cells, as shown by induced chromosomal abnormalities. Recent reports of allied
nature have shown that chromosomal damage can result from therapeutic doses
of radio-iodine (Boyd, Buchanan and Lennox, 1961) and the therapeutic or dia-
gnostic use of X-rays (Tough et al., 1960; Stewart and Sanderson, 1961).
Chromosome studies of bone marrow tissue were successfully completed in
pre-treatment samples from Case 1 and Case 3. Numerous myeloma cells were
present in both specimens. In Case 1, 30 metaphase plates showed chromosomes
ofnormal configuration, 28 cells having 46 chromosomes, 1 with 47, and 1 with 92.
The findings were essentially similar in 30 metaphase plates from Case 3, namely 29
cells with 46 chromosomes and 1 cell with 92 chromosomes, all of normal
morphology. Post-treatment samples did not grow successfully.
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1 2 3 4 5 6 1 8 9 10 11 12
13 14 15 16 11 18 19 20 21 22 X
1 2 3 4 5 6 8 9 10 11 12
13 14 15 16 17 18 19 20 21 22 X
FIG. 27.-Normal karyotype from huffy coat culture of Case 1.
FIG. 28.-Abnormal karyotype following treatment with NSC-1026 (Idiogram of same
metaphase plate depicted in Fig. 24).MUILTIPLE MYELOMA 699
SUMMARY AND CONCLUSIONS
Cultures of myeloma cells, from three cases of multiple myeloma, were grown
in vitro and their dynamic behaviour was recorded by time-lapse cinematography,
using phase-contrast optics. MIyeloma cells show characteristic movements in
the cell membrane, (1) rapid undulation, (2) pulsating pseudopodal extensions of
rhythmic nature, (3) a pseudopodal extension of cell cytoplasm similar to (2) in
shape but relatively static, (4) short fine membranous protrusions which extend
and retract rapidly. These activities are similar to those demonstrated by
Thiery (1960) in the normal rat plasma cell, and he has shown by electron
microscopy that the last type of membrane movement constitutes a process of
micropinocytosis. We can conclude that the dynamic behavioalr of the nmyeloma
cell is essentially similar to the plasma cell.
Morphological changes observed in tissue culture indicate that some myeloma
cells can transform into elongated spindle cells. The abundant endoplasmic
reticulum which is so characteristic of the plasma cell and the myeloma cell
observed with electron microscopy (Braunsteiner et al., 1957) has not been seen
by us in healthy myeloma cells using phase contrast optics, but we have been
able to demonstrate endoplasmic reticulum in the degenerating cell, when vacuo-
lization of the endoplasmic network is in progress.
Treatment of myeloma cells in vitro with 0X2 to 1 per cent 1-amino-cyclo-
pentanecarboxylic acid (NSC-1026) has demonstrated a peculiar reaction to
chemotherapy. The myeloma cells show spasmodic elongation and contraction,
while the nucleus repeatedly traverses from one end to the other of the elongated
cell. Finally, the damaged cell becomes rounded up and shows irreversible
injury. This reaction to chemotherapy appears to be characteristic for the plasma
cell and we have not observed such a change in previous time-lapse studies
employing cancer chemotherapeutic agents.
Buffy coat cultures of the peripheral blood failed to demonstrate any specific
chromosome " marker " in multiple myeloma. However, examination of buffy
coat cultures after in vivo treatment with NSC-1026, in one patient showed the
formation of abnormal karyotypes and chromosomal translocations, contrasting
with the normal appearances before treatment. We suggest that this technique
of buffy coat culture before and after therapy could give valuable information
regarding the efficacy and appropriate dosage level of newly elaborated chemo-
therapeutic agents, when these are being assessed in human cancer.
We are indebted to Dr. W. Benefiel and Dr. H. Moorman, of the Pasadena
Tumor Institute, for supplying material from myeloma patients. Mr. Charles
Raiborn and Mr. George Lefeber were responsible for the tissue culture and
photographic techniques involved in his study.
This investigation has been aided by a grant from The Jane Coffin Childs
Memorial Fund for Medical Research and in part by the U.S. Army Medical
Research and Development Command, Department of the Army, under Research
Grant No. DA-MEDDH-61-12.
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